Pediatrix Medical Group (NYSE:MD) Given New $15.00 Price Target at Mizuho

Pediatrix Medical Group (NYSE:MD - Free Report) had its price target upped by Mizuho from $13.00 to $15.00 in a research note published on Tuesday morning,Benzinga reports. They currently have a neutral rating on the stock.

A number of other equities research analysts also recently weighed in on the company. StockNews.com upgraded Pediatrix Medical Group from a "hold" rating to a "buy" rating in a research report on Wednesday, November 13th. Deutsche Bank Aktiengesellschaft upped their price objective on Pediatrix Medical Group from $9.00 to $15.00 and gave the company a "hold" rating in a report on Monday, November 4th. Truist Financial upped their price objective on Pediatrix Medical Group from $13.00 to $16.00 and gave the company a "hold" rating in a report on Monday, November 4th. UBS Group upped their price objective on Pediatrix Medical Group from $10.50 to $16.50 and gave the company a "neutral" rating in a report on Tuesday, November 5th. Finally, Jefferies Financial Group upped their price objective on Pediatrix Medical Group from $14.00 to $18.00 and gave the company a "buy" rating in a report on Tuesday, November 5th. Four research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Hold" and an average target price of $16.10.

Pediatrix Medical Group Price Performance

Pediatrix Medical Group stock traded up $0.12 on Tuesday, reaching $14.59. The company's stock had a trading volume of 547,083 shares, compared to its average volume of 865,818. The company has a market cap of $1.25 billion, a price-to-earnings ratio of -4.77, a PEG ratio of 2.03 and a beta of 1.55. Pediatrix Medical Group has a twelve month low of $6.62 and a twelve month high of $16.41. The company has a debt-to-equity ratio of 0.83, a quick ratio of 1.42 and a current ratio of 1.42. The business's fifty day moving average price is $12.69 and its 200 day moving average price is $9.93.

Pediatrix Medical Group (NYSE:MD - Get Free Report) last released its earnings results on Friday, November 1st. The company reported $0.44 earnings per share for the quarter, topping analysts' consensus estimates of $0.37 by $0.07. The company had revenue of $511.20 million during the quarter, compared to the consensus estimate of $498.87 million. Pediatrix Medical Group had a positive return on equity of 12.79% and a negative net margin of 12.65%. The firm's quarterly revenue was up .9% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.29 earnings per share. Equities analysts expect that Pediatrix Medical Group will post 1.25 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, Director Laura A. Linynsky sold 7,000 shares of the company's stock in a transaction dated Tuesday, August 27th. The stock was sold at an average price of $11.16, for a total transaction of $78,120.00. Following the completion of the transaction, the director now directly owns 30,805 shares of the company's stock, valued at $343,783.80. This represents a 18.52 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO James D. Swift sold 11,100 shares of the company's stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $10.79, for a total value of $119,769.00. Following the transaction, the chief executive officer now directly owns 170,001 shares of the company's stock, valued at $1,834,310.79. This represents a 6.13 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 53,808 shares of company stock worth $751,277 over the last ninety days. 1.20% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the company. Quest Partners LLC boosted its position in shares of Pediatrix Medical Group by 25.6% during the third quarter. Quest Partners LLC now owns 3,054 shares of the company's stock worth $35,000 after buying an additional 622 shares during the period. nVerses Capital LLC acquired a new position in Pediatrix Medical Group during the second quarter valued at approximately $31,000. Innealta Capital LLC acquired a new position in Pediatrix Medical Group during the second quarter valued at approximately $33,000. Quarry LP boosted its position in Pediatrix Medical Group by 54.1% during the third quarter. Quarry LP now owns 4,735 shares of the company's stock valued at $55,000 after purchasing an additional 1,662 shares during the last quarter. Finally, Nisa Investment Advisors LLC boosted its position in Pediatrix Medical Group by 47.2% during the second quarter. Nisa Investment Advisors LLC now owns 4,755 shares of the company's stock valued at $36,000 after purchasing an additional 1,524 shares during the last quarter. 97.71% of the stock is owned by institutional investors and hedge funds.

Pediatrix Medical Group Company Profile

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.